These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 1306523

  • 41. [Bromocriptine treatment of invasive giant prolactinomas prior to comprehensive treatments: results of a long-term follow up].
    Zhang HW, Yu CJ, Sun W, Yang J, Yan CX, Cun EH.
    Zhonghua Wai Ke Za Zhi; 2006 Nov 15; 44(22):1555-7. PubMed ID: 17359664
    [Abstract] [Full Text] [Related]

  • 42. Prolactinomas and pregnancy.
    Bronstein MD.
    Pituitary; 2005 Nov 15; 8(1):31-8. PubMed ID: 16411066
    [Abstract] [Full Text] [Related]

  • 43. Prolactinomas: evolution after menopause.
    Mallea-Gil MS, Manavela M, Alfieri A, Ballarino MC, Chervin A, Danilowicz K, Diez S, Fainstein Day P, García-Basavilbaso N, Glerean M, Guitelman M, Katz D, Loto MG, Martinez M, Miragaya K, Moncet D, Rogozinski AS, Servidio M, Stalldecker G, Vitale M, Boero L.
    Arch Endocrinol Metab; 2016 Feb 15; 60(1):42-6. PubMed ID: 26909481
    [Abstract] [Full Text] [Related]

  • 44. Quinagolide in the management of prolactinoma.
    Schultz PN, Ginsberg L, McCutcheon IE, Samaan N, Leavens M, Gagel RF.
    Pituitary; 2000 Dec 15; 3(4):239-49. PubMed ID: 11788012
    [Abstract] [Full Text] [Related]

  • 45. [Alteration of prolactin secretion after transsphenoidal adenomectomy for prolactinomas].
    Yokoyama M.
    No To Shinkei; 1990 Aug 15; 42(8):773-9. PubMed ID: 2223270
    [Abstract] [Full Text] [Related]

  • 46. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients.
    Ono M, Miki N, Kawamata T, Makino R, Amano K, Seki T, Kubo O, Hori T, Takano K.
    J Clin Endocrinol Metab; 2008 Dec 15; 93(12):4721-7. PubMed ID: 18812485
    [Abstract] [Full Text] [Related]

  • 47. Late development of resistance to bromocriptine in a patient with macroprolactinoma.
    Delgrange E, Crabbé J, Donckier J.
    Horm Res; 1998 Dec 15; 49(5):250-3. PubMed ID: 9568811
    [Abstract] [Full Text] [Related]

  • 48. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients.
    Primeau V, Raftopoulos C, Maiter D.
    Eur J Endocrinol; 2012 May 15; 166(5):779-86. PubMed ID: 22301915
    [Abstract] [Full Text] [Related]

  • 49. DNA synthesis by pituitary tumours, with reference to plasma hormone levels and to effects of bromocriptine.
    Lloyd HM, Jacobi JM, Willgoss DA.
    Clin Endocrinol (Oxf); 1995 Jul 15; 43(1):79-85. PubMed ID: 7641414
    [Abstract] [Full Text] [Related]

  • 50. A case of large prolactinoma supposed to be cured by bromocriptine therapy.
    Arita K, Uozumi T, Ohta M.
    Endocrinol Jpn; 1988 Jun 15; 35(3):503-9. PubMed ID: 3197661
    [Abstract] [Full Text] [Related]

  • 51. Treatment of extensively invasive (giant) prolactinomas with bromocriptine.
    Grebe SK, Delahunt JW, Feek CM.
    N Z Med J; 1992 Apr 08; 105(931):129-31. PubMed ID: 1560924
    [Abstract] [Full Text] [Related]

  • 52. Effects of quinagolide (CV 205-502), a selective D2-agonist, on vascular reactivity in patients with a prolactin-secreting adenoma.
    Bodmer CW, Atkin SL, Savage MW, Masson EA, White MC.
    Clin Endocrinol (Oxf); 1995 Jul 08; 43(1):49-53. PubMed ID: 7641411
    [Abstract] [Full Text] [Related]

  • 53. Treatment of macroprolactinomas with a new non-ergot, long-acting dopaminergic drug, CV 205-502.
    van't Verlaat JW, Croughs RJ, Brownell J.
    Clin Endocrinol (Oxf); 1990 Nov 08; 33(5):619-24. PubMed ID: 1979262
    [Abstract] [Full Text] [Related]

  • 54. Giant invasive prolactinoma: a case report and review of nine further cases.
    Davis JR, Sheppard MC, Heath DA.
    Q J Med; 1990 Mar 08; 74(275):227-38. PubMed ID: 2385731
    [Abstract] [Full Text] [Related]

  • 55. Dopamine resistance of prolactinomas.
    Molitch ME.
    Pituitary; 2003 Mar 08; 6(1):19-27. PubMed ID: 14674720
    [Abstract] [Full Text] [Related]

  • 56. Endocrine function, psychiatric and clinical consequences in patients with macroprolactinomas after long-term treatment with the new non-ergot dopamine agonist CV205-502.
    Barnett PS, Palazidou E, Miell JP, Coskeran PB, Butler J, Dawson JM, Maccabe J, McGregor AM.
    Q J Med; 1991 Nov 08; 81(295):891-906. PubMed ID: 1687293
    [Abstract] [Full Text] [Related]

  • 57. [Prolactinoma in man: clinical and histological characteristics].
    Trouillas J, Delgrange E, Jouanneau E, Maiter D, Guigard MP, Donckier J, Perrin G, Jan M, Tourniaire J.
    Ann Endocrinol (Paris); 2000 Sep 08; 61(3):253-7. PubMed ID: 10970951
    [Abstract] [Full Text] [Related]

  • 58. Results of primary treatment with bromocriptine of prolactinomas with extrasellar extension.
    van 't Verlaat JW, Croughs RJ, Hendriks MJ, Bosma NJ.
    Can J Neurol Sci; 1990 Feb 08; 17(1):71-3. PubMed ID: 2311021
    [Abstract] [Full Text] [Related]

  • 59. Clinical profile and long term follow up of children and adolescents with prolactinomas.
    Acharya SV, Gopal RA, Bandgar TR, Joshi SR, Menon PS, Shah NS.
    Pituitary; 2009 Feb 08; 12(3):186-9. PubMed ID: 18946737
    [Abstract] [Full Text] [Related]

  • 60. Growth of prolactinoma despite lowering of serum prolactin by bromocriptine.
    Kupersmith MJ, Kleinberg D, Warren FA, Budzilovitch G, Cooper P.
    Neurosurgery; 1989 Mar 08; 24(3):417-23. PubMed ID: 2927618
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.